

Serial No.: 09/888,370

-2-

Group Art Unit: 1632

34. (New) The method of claim 28, wherein said agent stimulates c-Maf activity.

35. (New) The method of claim 28, wherein said agent modulates c-Maf activity by modulating the activity of the c-Maf polypeptide.

36. (New) The method of claim 28, wherein said agent modulates c-Maf activity by modulating the transcription of the c-Maf gene.

37. (New) The method of claim 28, wherein said agent modulates c-Maf activity by modulating the transcription of the c-Maf mRNA.

38. (New) The method of claim 28, wherein said agent that modulates c-Maf activity is selected from the group consisting of antisense nucleic acid molecules, antibodies, dominant negative inhibitors, c-Maf nucleic acid molecules, and chemical compounds.--

REMARKS

Claims 27-32 were pending in the application. New claims 33-38 have been added.

Accordingly, 27-38 are currently pending.

No new matter has been added to the application by way of the amendments to the claims. Support for the newly added claims can be found in the application as originally filed. Specifically, support for new claims 33-37 can be found at page 34, lines 9-22 of the specification. Support for new claim 38 can be found at, for example, page 34, line 20 through page 40, line 15 of the specification.

RESPONSE TO RESTRICTION REQUIREMENT

The Examiner has required restriction to one of the following groups:

Group I: Claim 27, drawn to a method of detecting the presence of human c-Maf in a biological sample.

Group II: Claim 28, drawn to a method for modulating human c-Maf activity in a cell;